Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective lowered by Piper Sandler from $10.00 to $6.00 in ...
Stock analysts at StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a ...
We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...
Stevanato's 2024 revenue hits €1.1B, driven by biopharma growth! Discover how facility expansions & rising demand are transforming their market impact.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback